Author

B. K. Law

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:cell signaling & trafficking· 4 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

M. E. Law· 4 shared R. K. Castellano· 3 shared B. J. Davis· 2 shared C. D. Heldermon· 2 shared C.-W. Chiang· 2 shared E. Yaaghubi· 2 shared M. Wang· 2 shared O. A. Guryanova· 2 shared

Activity by Year

2021-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. E. Law

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

DR5 disulfide bonding as a sensor and effector of protein folding stress

M. E. Law, Z. M. Dulloo, S. R. Eggleston, G. P. Takacs, G. M. Alexandrow, M. Wang, H. Su, B. A. Forsyth, C.-W. Chiang, A. Sharma, S. R. R. Kanumuri, O. A. Guryanova, J. K. Harrison, B. Tirosh, R. K. Castellano, B. K. Law

This study shows that disrupting DR5 disulfide bonds activates pro-apoptotic signaling and reveals DR5 disulfide bonding as a sensor and effector of ER stress in cancer cells.

bioRxiv · Mar 4, 2024 · PreprintCancer Biology

A molecular glue approach to control the half-life of CRISPR-based technologies

V. Sreekanth, M. Jan, K. T. Zhao, D. Lim, J. R. Davis, M. McConkey, V. Kovalcik, S. Barkal, B. K. Law, J. Fife, R. Tian, M. E. Vinyard, B. Becerra, M. E. Kampmann, R. I. Sherwood, , A. Choudhary

This paper introduces a molecular glue approach using pomalidomide to control the half-life of CRISPR-based technologies, enabling precise regulation of their activity and therapeutic potential.

bioRxiv · Mar 12, 2023Bioengineering

Repurposing Tranexamic Acid as an Anticancer Agent

M. E. Law, B. J. Davis, A. F. Ghilardi, E. Yaaghubi, Z. M. Dulloo, M. Wang, O. Guryanova, C. D. Heldermon, R. K. Castellano, B. K. Law

This study shows Tranexamic Acid inhibits cancer growth by blocking Plasmin-mediated CDCP1 cleavage and disrupts multiple intracellular signaling pathways.

bioRxiv · Oct 17, 2021 · PreprintCancer Biology

Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A

S. Narayan, A. Raza, I. Mahmud, N. Koo, T. Garrett, M. E. Law, B. K. Law, A. K. Sharma

This study identifies NSC49L as a PP2A agonist that sensitizes FOLFOX-resistant colorectal cancer cells to TRAIL by downregulating the AKT1/mTOR/4EBP1-axis and p21 translation.

bioRxiv · Jul 21, 2021Cancer Biology

DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks

K. Venugopal, P. Nowialis, Y. Feng, D. E. Shabashvili, C. M. Berntsen, K. I. Krajcik, C. Taragjini, Z. Zaroogian, H. L. Casellas-Roman, L. M. Posada, C. Gunaratne, J. Li, D. Dupere-Richer, R. L. Bennett, S. Pondugula, , O. A. Guryanova

This study shows that DNMT3A mutations impair replication fork recovery, leading to DNA damage and sensitivity to nucleoside analogs like cytarabine.

bioRxiv · May 28, 2021Cancer Biology

Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death

M. E. Law, E. Yaaghubi, A. Ghilardi, B. J. Davis, R. B. Ferreira, J. Koh, S. Chen, S. F. DePeter, C. M. Schilson, C.-W. Chiang, C. D. Heldermon, P. Norgaard, R. K. Castellano, B. K. Law

This study identifies DDAs as inhibitors of AGR2 and ERp44, showing they induce DR4/5 oligomerization and cancer cell death via disrupting disulfide bonds.

bioRxiv · Jan 13, 2021Pharmacology & Toxicology